Key result
Soluble ST2 is a strong predictor of cardiovascular outcomes in both chronic and acute heart failure, adding prognostic value to natriuretic peptides and potentially guiding therapy.
Why the study?
Does soluble ST2 testing improve risk stratification compared to or in addition to natriuretic peptides in patients with heart failure?
Does soluble ST2 testing improve risk stratification compared to or in addition to natriuretic peptides in patients with heart failure?
Soluble ST2 is a promising biomarker for risk stratification and potentially guiding therapy in heart failure, providing additive or superior prognostic value to natriuretic peptides.
Supports sST2 for HF risk stratification beyond NPs; leaves open whether testing improves outcomes or guides therapy.
ST2 is a member of the interleukin-1 receptor family biomarker and circulating soluble ST2 concentrations are believed to reflect cardiovascular stress and fibrosis. Recent studies have demonstrated soluble ST2 to be a strong predictor of cardiovascular outcomes in both chronic and acute heart failure. It is a new biomarker that meets all required criteria for a useful biomarker. Of note, it adds information to natriuretic peptides (NPs) and some studies have shown it is even superior in terms of risk stratification. Since the introduction of NPs, this has been the most promising biomarker in the field of heart failure and might be particularly useful as therapy guide.
No takes yet. Share an insight, caveat, or question.
Villacorta et al. (2015) conducted a review in Heart Failure. Soluble ST2 testing was evaluated. Soluble ST2 is a strong predictor of cardiovascular outcomes in both chronic and acute heart failure, adding prognostic value to natriuretic peptides and potentially guiding therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: